Pharmacists clad in white coats packed the Capitol steps calling for reform of pharmacy benefit managers (PBM). trib.al/8ZQo1sr

The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead DCI's latest #PBM data, along with a preview of the next few years. CVS Health $CVS Express Scripts Pharmacy Benefit Services $CI OptumRx $UNH drugch.nl/4au5JWU drugch.nl/4au5JWU

Commentary in Daily Republic News: Why lawmakers must protect new treatments dailyrepublic.com/opinion/commen…

We can help patients and lower costs by: 1. Getting rebates to patients 2. Fixing misaligned incentives in the market 3. Stopping insurers from denying patient access to innovative medicines that treat & prevent disease Get the facts here: phrma.org/blog/what-rece…

Again, Sen. Bernie Sanders is attacking an innovative company to advance a political agenda instead of addressing the real cause of affordability challenges. Policymakers should be encouraging new medicines that improve health and avoid the most expensive parts of our health care.

Every time new medicines are approved, insurers say they can’t afford to cover them and use that as an excuse to deny people access. Why is Sen. Bernie Sanders giving insurers a free pass instead of holding them accountable so that insurance works like it should?

UnitedHealth Group is the biggest employer of doctors and the largest health insurer. Its holdings are vast. Know what else United owns? A bank. It’s called Optum Bank. And it's had problems. 🧵

Five questions for today’s hearings with UnitedHealth CEO Andrew Witty, including if their size is safe for the country + if their for-profit mindset is good for patients. $UNH washingtonpost.com/politics/2024/…

Great conversation recently at @FTLive’s US Pharma and Biotech Summit with Oliver Barnes, @EMDSerono’s Terri Stewart and Eric Gascho about policies like government price setting that put R&D and patient access in jeopardy, especially in an election year. #FTPharma

The FTC just released an interim report on pharmacy benefit managers, the dominant middlemen who hike the cost of prescriptions, including overcharging patients for cancer drugs. 1/13

Another day, another damning report on the havoc caused by the largest PBMs. It shouldn’t be a surprise that voters across the country want policymakers to hold PBMs accountable.

The FTC report confirms PBMs profit at the expense of patients. Read all about it here: phrma.org/Blog/FTC-repor…

PBMs and health insurers decide what medicines you can get, and they set the price you pay at the pharmacy. At the same time, over half of every dollar spent on medicines goes to these middlemen and others. Find out more: phrma.org/Blog/PhRMA-Lau…

In about 15 minutes executives from the big 3 PBMs will face the House Oversight committee. Earlier this morning we exclusively reported that committee investigators found PBMs increase costs and take away choices for patients. wsj.com/health/pharma/… via The Wall Street Journal

I sat down with Nicole DeFeudis to talk about the flawed and political government price-setting process and the need for PBM reforms like sharing the savings with patients at the pharmacy. Read the interview with Endpoints News here: endpts.com/qa-phrma-ceo-s…

Don’t be fooled by today’s announcement on the government-set prices for 10 innovative medicines. The government arbitrarily set prices for these medicines to drive headlines ahead of the election. Let’s take a look at what’s already happening in the market: -Since the start of

The IRA is just beginning to go into effect, but it is already resulting in significant unintended consequences for Medicare beneficiaries. New surveys reveal how insurers and their PBMs will limit treatment options for seniors. phrma.org/Blog/New-surve…

Today, Robert Zirkelbach joined the RealClearPolitics team to discuss the upcoming election, the latest voter priorities and key findings from their new survey. Watch the full webinar here: realclearpolitics.com/2024_election_…

PhRMA Rolls Out Ad Pushing PBM Reform Amid Lame-Duck Uncertainty ow.ly/MN8x105OEtv

PBMs treat their contracts like fight club—they won't talk about them. In a conversation with Merck CEO Robert M. Davis, Mark Cuban broke down the lack of transparency from PBMs, and how patients, employers and taxpayers continue to pay the price.